This page shows the publications co-authored by John Mullen and Jennifer Wo.
ASO Visual Abstract: Neoadjuvant versus Postoperative Chemoradiotherapy Is Associated with Improved Survival in Patients with Resectable Gastric and Gastroesophageal Cancer. Ann Surg Oncol. 2021 Dec; 28(Suppl 3):690-691.
Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer. Ann Surg Oncol. 2022 Jan; 29(1):242-252.
Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clin Cancer Res. 2021 12 01; 27(23):6343-6353.
Impact of Treatment Sequencing on Survival for Patients with Locally Advanced Gastric Cancer. Ann Surg Oncol. 2021 May; 28(5):2856-2865.
Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer. J Am Coll Surg. 2020 06; 230(6):912-924.
Predictors of Lymph Node Metastasis in Western Early Gastric Cancer. J Gastrointest Surg. 2016 Mar; 20(3):531-8.
Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 09 01; 109(9).
The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation. Am J Clin Oncol. 2016 06; 39(3):243-7.
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.